Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 25, 2002

View Archived Issues

New anti-H. pylori agents identified by American researchers

Dual DHFR/TS inhibitors with potential in cancer and opportunistic infections

Novel VEGFR inhibitors prepared and tested at Taisho

HE-2500, HE-2200 prove effective in animal models of multiple sclerosis

Immunomodulatory effects described for simvastatin in PBMCs from MS patients

New product for cancer heading for clinical testing at ProMetic

First nucleotide analogue for HBV approved by FDA

Worldwide development and marketing agreement for epothilone D in cancer

Forest withdraws NDA to amend and refile later this year

First Rigel compound enters clinical testing for allergic rhinitis

Potential new antidepressant presented by Faes in Toledo

Pharmacokinetics of components of AVP-923 examined in poor and extensive metabolizers

Candidate malaria vaccine emerges from research by Australian and U.S. scientists

Antibacterial quinolones in early development at Pharmacia

Kaken identifies VLA-4 antagonists

Fujisawa and Pharmagenesis collaborate on triptolide derivatives

Benefits of tiotropium in COPD become evident upon withdrawal

FDA issues approvable letter for Metvix

Trospium meets endpoints in phase III overactive bladder trial

Tarceva receives second fast track designation

Phase I cleared for Islet Neogenesis Therapy

Safety data for omalizumab reported at the 2002 ERS congress

Clopidogrel approved in E.U. for patients with acute coronary syndrome

Biotica expands macrolide antiinfective research collaboration with Pfizer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...